KR20150044877A - 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 - Google Patents

디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 Download PDF

Info

Publication number
KR20150044877A
KR20150044877A KR20157001763A KR20157001763A KR20150044877A KR 20150044877 A KR20150044877 A KR 20150044877A KR 20157001763 A KR20157001763 A KR 20157001763A KR 20157001763 A KR20157001763 A KR 20157001763A KR 20150044877 A KR20150044877 A KR 20150044877A
Authority
KR
South Korea
Prior art keywords
biological activity
fibrotide
plasmin
rti
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157001763A
Other languages
English (en)
Korean (ko)
Inventor
테렌지오 이그노니
비제이 쿠마르
칼리드 이슬람
Original Assignee
젠티엄 에스피에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46829846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150044877(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 젠티엄 에스피에이 filed Critical 젠티엄 에스피에이
Publication of KR20150044877A publication Critical patent/KR20150044877A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR20157001763A 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 Ceased KR20150044877A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000193 WO2013190582A1 (en) 2012-06-22 2012-06-22 Euglobulin-based method for determining the biological activity of defibrotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187024264A Division KR101948243B1 (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법

Publications (1)

Publication Number Publication Date
KR20150044877A true KR20150044877A (ko) 2015-04-27

Family

ID=46829846

Family Applications (4)

Application Number Title Priority Date Filing Date
KR20157001763A Ceased KR20150044877A (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
KR1020197028118A Ceased KR20190112197A (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
KR1020197003854A Active KR102038357B1 (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
KR1020187024264A Active KR101948243B1 (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197028118A Ceased KR20190112197A (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
KR1020197003854A Active KR102038357B1 (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
KR1020187024264A Active KR101948243B1 (ko) 2012-06-22 2012-06-22 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법

Country Status (16)

Country Link
US (9) US9902952B2 (https=)
EP (1) EP2864496B2 (https=)
JP (1) JP6198821B2 (https=)
KR (4) KR20150044877A (https=)
CN (2) CN110079580B (https=)
AU (1) AU2012383169B2 (https=)
BR (1) BR112014031934B1 (https=)
CA (1) CA2874960C (https=)
DK (1) DK2864496T4 (https=)
ES (1) ES2660969T5 (https=)
IL (1) IL236132B (https=)
IN (1) IN2014DN10584A (https=)
MX (1) MX352085B (https=)
RU (1) RU2627177C2 (https=)
SG (1) SG11201408481UA (https=)
WO (1) WO2013190582A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN110249399B (zh) * 2017-01-25 2022-05-03 凯米特电子公司 自衰减mlcc阵列
JP2020530004A (ja) * 2017-08-03 2020-10-15 ジャズ ファーマシューティカルズ アイルランド リミテッド 核酸を高濃度で含む製剤
CN112236149A (zh) 2018-04-12 2021-01-15 贾兹制药公司 用于预防和治疗细胞因子释放综合征和与免疫耗竭相关的神经毒性的去纤苷
WO2020118165A1 (en) 2018-12-07 2020-06-11 Jazz Pharmaceuticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581722B2 (ja) * 1986-04-17 1997-02-12 クリノス・インドウストリア・フアルマコビオロジカ・ソチエタ・ペル・アチオニ 化学的に定義された再現性のあるポリデオキシリボヌクレオチドを得る方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170215B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
JPH0539280A (ja) * 1990-07-20 1993-02-19 Takeda Chem Ind Ltd サツカロアスコルビン酸誘導体および血栓症予防治療剤
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5856444A (en) 1994-11-30 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Thrombocytopoiesis stimulating factor
ATE299030T1 (de) 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
HK1044896A1 (zh) 1997-04-28 2002-11-08 Burcoglu Arsinur 治疗hiv感染和与之有关的继发感染的方法
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
JP2003503313A (ja) 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
ATE311907T1 (de) 1999-06-08 2005-12-15 Gentium Spa Anwendung von komplexen von kationischen liposomen und polydeoxyribonukleotiden wie arzneimitteln
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
EP1356071B1 (en) 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
UA83628C2 (ru) 2002-05-31 2008-08-11 Клиникум Дер Универзитет Регенсбург Способ защиты эндотелиальных и эпителиальных клеток во время трансплантации алогенных стволовых клеток
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
RU2005101621A (ru) 2002-07-01 2005-11-20 Савиент Фармасьютикалс, Инк. (Us) Антитела и их применения
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
CA2623142C (en) * 2004-09-22 2016-01-19 The Regents Of The University Of Colorado, A Body Corporate Methods for a global assay of coagulation and fibrinolysis
US7723127B2 (en) 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
WO2006094916A1 (en) 2005-03-03 2006-09-14 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
EP2183598A1 (en) 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
CN101301306A (zh) 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防休克药物中的应用
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011057143A1 (en) * 2009-11-06 2011-05-12 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for simultaneous assay of thrombin and plasmin generation
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
JP2020530004A (ja) 2017-08-03 2020-10-15 ジャズ ファーマシューティカルズ アイルランド リミテッド 核酸を高濃度で含む製剤
WO2020118165A1 (en) 2018-12-07 2020-06-11 Jazz Pharmaceuticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581722B2 (ja) * 1986-04-17 1997-02-12 クリノス・インドウストリア・フアルマコビオロジカ・ソチエタ・ペル・アチオニ 化学的に定義された再現性のあるポリデオキシリボヌクレオチドを得る方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biol Blood Marrow Transplant. 2010, 제16권 제1005-1017면 *
Cardiovascular Drug Reviews., vol.9, no.2, p.172-196 (1991) *

Also Published As

Publication number Publication date
EP2864496B1 (en) 2017-11-29
ES2660969T5 (es) 2021-09-03
US11085043B2 (en) 2021-08-10
US12534722B2 (en) 2026-01-27
KR20190016148A (ko) 2019-02-15
US9902952B2 (en) 2018-02-27
US20230357762A1 (en) 2023-11-09
US20210388350A1 (en) 2021-12-16
SG11201408481UA (en) 2015-01-29
KR102038357B1 (ko) 2019-10-31
RU2014149089A (ru) 2016-08-10
BR112014031934B1 (pt) 2021-05-04
US20180334672A1 (en) 2018-11-22
CN110079580B (zh) 2022-12-06
IL236132B (en) 2018-07-31
US12529052B2 (en) 2026-01-20
MX2014016114A (es) 2015-09-23
DK2864496T3 (en) 2018-01-15
KR20190112197A (ko) 2019-10-02
DK2864496T4 (da) 2021-01-04
ES2660969T3 (es) 2018-03-26
AU2012383169A1 (en) 2015-01-15
KR20180098420A (ko) 2018-09-03
US11236328B2 (en) 2022-02-01
EP2864496B2 (en) 2020-11-25
CN110079580A (zh) 2019-08-02
US20250075206A1 (en) 2025-03-06
WO2013190582A1 (en) 2013-12-27
AU2012383169B2 (en) 2017-12-21
MX352085B (es) 2017-11-08
US11746348B2 (en) 2023-09-05
JP2015521477A (ja) 2015-07-30
CA2874960A1 (en) 2013-12-27
US20250236866A1 (en) 2025-07-24
RU2627177C2 (ru) 2017-08-03
US20210363519A1 (en) 2021-11-25
IL236132A0 (en) 2015-01-29
EP2864496A1 (en) 2015-04-29
US20150176003A1 (en) 2015-06-25
US20250236867A1 (en) 2025-07-24
KR101948243B1 (ko) 2019-05-21
JP6198821B2 (ja) 2017-09-20
HK1208503A1 (en) 2016-03-04
CN104619857A (zh) 2015-05-13
CA2874960C (en) 2021-05-18
US20200208148A1 (en) 2020-07-02
BR112014031934A8 (pt) 2018-01-02
IN2014DN10584A (https=) 2015-08-28
BR112014031934A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
KR101948243B1 (ko) 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
JP4348192B2 (ja) デフィブロチドの生物学的活性を決定する方法
AU2002360945A2 (en) A method for determining the biological activity of defibrotide
RU2766143C2 (ru) Жидкая композиция дефибротида для лечения и профилактики веноокклюзионной болезни
TWI615473B (zh) 用於測定去纖維蛋白多核苷酸的生物活性之基於優球蛋白的方法
HK1208503B (en) Euglobulin-based method for determining the biological activity of defibrotide
SA113350049B1 (ar) طريقة تعتمد على جلوبولين حقيقي لتحديد النشاط الحيوي لديفيبروتيد

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180102

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180621

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180621

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180302

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180801

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180709

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180621

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180302

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180102

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180823